Immutep to Present Eftilagimod Alfa Survival Data at ASCO 2026 Poster Session
Immutep secured a poster presentation at ASCO 2026 on May 30, detailing eftilagimod alfa’s mechanism as an MHC class II APC activator that rapidly and sustainably enhances lymphocyte activation. Data from multiple late-stage cancer trials linked these immune activation markers to improved overall survival in metastatic patients.
1. Abstract Acceptance
Immutep Limited announced that an abstract on eftilagimod alfa has been accepted for poster presentation at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago.
2. Eftilagimod Alfa Data
The abstract presents cumulative results from multiple late-stage cancer studies showing that eftilagimod alfa, an MHC class II APC activator, induces rapid and sustained lymphocyte activation correlated with improved overall survival in metastatic patients.
3. Presentation Logistics
The poster titled “Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients” will be presented on May 30, 1:30–4:30 PM CDT at Poster Board 359 (Abstract #2569) during the Developmental Therapeutics—Immunotherapy session.